{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:56:26Z","timestamp":1794473786343,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.euros.2023.07.007","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T18:15:08Z","timestamp":1692728108000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Low Alanine Aminotransferase, as a Marker of Sarcopenia and Frailty, Is Associated with Shorter Survival Among Prostate Cancer Patients and Survivors. A Retrospective Cohort Analysis of 4064 Patients"],"prefix":"10.1016","volume":"55","author":[{"given":"Menachem","family":"Laufer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Perelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Sarfaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Itelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-3245","authenticated-orcid":false,"given":"Gad","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2023.07.007_b0005","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1002\/cam4.4125","article-title":"Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with radium-223","volume":"10","author":"Al-Ezzi","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.euros.2023.07.007_b0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.eururo.2014.01.030","article-title":"Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status","volume":"67","author":"Azad","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2023.07.007_b0015","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.afos.2021.03.002","article-title":"Sarcopenia and mortality in cancer: a meta-analysis","volume":"7","author":"Au","year":"2021","journal-title":"Osteoporos Sarcopenia"},{"key":"10.1016\/j.euros.2023.07.007_b0020","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.2014.55.0962","article-title":"Surgical considerations in older adults with cancer","volume":"32","author":"Korc-Grodzicki","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2023.07.007_b0025","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2023.07.007_b0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2023.07.007_b0035","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2011.38.8850","article-title":"Sarcopenia during androgen-deprivation therapy for prostate cancer","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2023.07.007_b0040","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.urology.2012.10.050","article-title":"Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers","volume":"81","author":"Hara","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.euros.2023.07.007_b0045","doi-asserted-by":"crossref","first-page":"e127018","DOI":"10.1172\/jci.insight.127018","article-title":"Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopenia","volume":"5","author":"Pan","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.euros.2023.07.007_b0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.juro.2018.01.069","article-title":"Subcutaneous fat distribution is a prognostic biomarker for men with castration resistant prostate cancer","volume":"200","author":"Lee","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2023.07.007_b0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.prnil.2018.04.002","article-title":"Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy","volume":"7","author":"Ohtaka","year":"2019","journal-title":"Prostate Int"},{"key":"10.1016\/j.euros.2023.07.007_b0060","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/j.clgc.2017.11.003","article-title":"The association between sarcopenia and oncologic outcomes after radical prostatectomy","volume":"16","author":"Mason","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2023.07.007_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.722652","article-title":"Muscle loss during androgen deprivation therapy is associated with higher risk of non-cancer mortality in high-risk prostate cancer","volume":"11","author":"Chiang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.euros.2023.07.007_b0070","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.3390\/cancers13246345","article-title":"Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euros.2023.07.007_b0075","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/neuros\/nyz216","article-title":"Sarcopenia predicts overall survival in patients with lung, breast, prostate, or myeloma spine metastases undergoing stereotactic body radiation therapy (SBRT), independent of histology","volume":"86","author":"Zakaria","year":"2020","journal-title":"Neurosurgery"},{"key":"10.1016\/j.euros.2023.07.007_b0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.34596","article-title":"Body composition and mortality in men receiving prostate radiotherapy: a pooled analysis of NRG\/RTOG 9406 and NRG\/RTOG 0126","volume":"129","author":"McDonald","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2023.07.007_b0085","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MOU.0000000000000885","article-title":"The prognostic value of sarcopenia in patients with prostate cancer: a systematic review","volume":"31","author":"Jahrreiss","year":"2021","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euros.2023.07.007_b0090","doi-asserted-by":"crossref","first-page":"103.e9","DOI":"10.1016\/j.urolonc.2021.08.009","article-title":"CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: a systematic review and meta-analysis","volume":"40","author":"Meyer","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2023.07.007_b0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jcm12010057","article-title":"Prognostic impact of sarcopenia in patients with advanced prostate carcinoma: a systematic review","volume":"12","author":"de Pablos-Rodr\u00edguez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.euros.2023.07.007_b0100","doi-asserted-by":"crossref","first-page":"925","DOI":"10.7150\/ijms.8951","article-title":"Alanine aminotransferase\u2014old biomarker and new concept: a review","volume":"11","author":"Liu","year":"2014","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.euros.2023.07.007_b0105","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3390\/jcm9082659","article-title":"Frailty and sarcopenia assessment upon hospital admission to internal medicine predicts length of hospital stay and re-admission: a prospective study of 980 patients","volume":"9","author":"Anani","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.euros.2023.07.007_b0110","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/aje\/kwt209","article-title":"The association of low serum alanine aminotransferase activity with mortality in the US population","volume":"178","author":"Ruhl","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.euros.2023.07.007_b0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2023.07.007_b0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamaoncol.2018.5327","article-title":"Association of body fat and risk of breast cancer in postmenopausal women with normal body mass index: a secondary analysis of a randomized clinical trial and observational study","volume":"5","author":"Iyengar","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euros.2023.07.007_b0125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2023.07.007_b0130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1152\/jappl.1998.85.1.115","article-title":"Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography","volume":"85","author":"Mitsiopoulos","year":"1998","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.euros.2023.07.007_b0135","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.2147\/CMAR.S195869","article-title":"L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients","volume":"11","author":"Portal","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.euros.2023.07.007_b0140","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00384-017-2773-0","article-title":"Morphologic change of the psoas muscle as a surrogate marker of sarcopenia and predictor of complications after colorectal cancer surgery","volume":"32","author":"Hanaoka","year":"2017","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.euros.2023.07.007_b0145","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","article-title":"The prevalence and outcomes of frailty in older cancer patients: a systematic review","volume":"26","author":"Handforth","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2023.07.007_b0150","first-page":"362","article-title":"Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology","volume":"67","author":"Ethun","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2023.07.007_b0155","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ejim.2014.10.019","article-title":"Low ALT blood levels predict long-term all-cause mortality among adults. A historical prospective cohort study","volume":"25","author":"Ramaty","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.euros.2023.07.007_b0160","doi-asserted-by":"crossref","first-page":"e33659","DOI":"10.1097\/MD.0000000000033659","article-title":"Low ALT, a marker of sarcopenia and frailty, is associated with shortened survival amongst myelodysplastic syndrome patients: a retrospective study","volume":"102","author":"Uliel","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.euros.2023.07.007_b0165","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/cncr.23084","article-title":"Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review","volume":"110","author":"Bylow","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2023.07.007_b0170","doi-asserted-by":"crossref","first-page":"426.e1","DOI":"10.1016\/j.urolonc.2015.06.002","article-title":"Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools","volume":"33","author":"Lascano","year":"2015","journal-title":"Urol Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168323003932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168323003932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:09:19Z","timestamp":1762978159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168323003932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":34,"alternative-id":["S2666168323003932"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2023.07.007","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Alanine Aminotransferase, as a Marker of Sarcopenia and Frailty, Is Associated with Shorter Survival Among Prostate Cancer Patients and Survivors. A Retrospective Cohort Analysis of 4064 Patients","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2023.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}